– Aberrant TRIM7 expression identified as a key driver of immune checkpoint blockade (ICB) acquired resistance; inhibition of TRIM7 with small molecule inhibitors may prevent or reverse acquired resistance to PD-1/L1 blockade –
Shattuck Labs Anuncia Apresentação Oral de Dados Pré-clínicos na Reunião Anual da American Association for Cancer Research (AACR) 2024
